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Background: Despite the frequency of oral involvement, there are unexpectedly few studies 
of either on the oral manifestations of pemphigus or their long-term management, and 
diagnostic delay in Dentistry is frequent.  
Methods: We have examined outcome of patients presenting with predominantly oral 
pemphigus vulgaris (PV). Ninety-eight subjects were followed-up for 85.12 months and 
treated with systemic steroids; 48 of them received adjunctive therapy with azathioprine, 16 
with rituximab, 13 with mycophenolate mofetil, 3 with immunoglobulin, 1 with dapsone. 
Results: Clinical remission was achieved in 80 patients (84.21%); 39 of them were off 
therapy and 41 on therapy. Fifteen patients were not in remission, having been under 
systemic therapy for 72.16 months. Sixty-nine patients developed detectable adverse 
effects. Two fatal outcomes were recorded. Each additional year of steroid therapy ensured 
47% chance of developing 1 or 2 side effects, and 64% chance of developing more than 3 
(ORs 1.47, CI 1.162-1.903; ORs 1.64, CI 1.107-2.130, respectively).  
Conclusion: In one of the largest available cohort with the longest follow-up ever reported, 
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INTRODUCTION 
Pemphigus is a group of potentially life-threatening and organ-specific autoimmune 
diseases, characterized by cutaneous and/or mucosal blistering.1-4 Pemphigus can be 
mainly classified into 4 types: pemphigus vulgaris, pemphigus vegetans, pemphigus 
erythematosus and pemphigus foliaceus.5 Pemphigus vulgaris (PV), the most common 
variant, is characterized by circulating IgG antibodies mainly directed against desmoglein 3 
(Dsg3), with about half the patients also having Dsg1 autoantibodies.6-8 Available 
epidemiological data suggest that PV affects 0.1-0.5 patients per 100.000 population per 
year.9 The lesions of PV characteristically occur first in the oropharyngeal mucosa and later 
in the skin; other mucosae (e.g. oesophageal, genitalia and conjunctiva) may be involved 
as well.1 The invariably fatal outcome of PV has changed dramatically since the 1950s, with 
the advent of corticosteroids.4,9 However, there is a lack of consensus in the literature about 
the treatment of this disorder and this issue is further complicated by the fact that the therapy 
has to be individualized.10,11 
Despite the frequency of oral involvement, there are unexpectedly few studies of either on 
the oral manifestations of pemphigus or their long-term management,9,12-16 and diagnostic 
delay in Dentistry is frequent.17  
The aim of this retrospective hospital-based study was to examine the different clinical 
features and treatment outcomes of Italian patients presenting with PV predominantly 
affecting the oral cavity.  
 
MATERIALS AND METHODS 
   Study population 
The case records of all new patients, admitted within the years 1993 to 2018, were reviewed. 
Medical and present complaint histories were acquired at the first consultation. The 
diagnosis was confirmed by histopathological examination with haematoxylin and eosin 
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staining, and direct immunofluorescence analysis. Assay of serum antibody titres by indirect 
immunofluorescence have been taken at the time of the first biopsy until 2004; later, the 
diagnosis was completed with the serum detection of antidesmosomal antibodies against 
desmoglein 1 (Dsg1) and/or desmoglein 3 (Dsg3). 
 
   Treatment 
Patients mainly received treatment with systemic corticosteroids (typical starting dose of 1-
1.5 mg/kg per day of prednisone, for variable lengths of time usually of 2-4 months), alone 
or with azathioprine (at typical starting dose of 2 mg/kg per day), depending by clinical 
severity; corticosteroids were then tapered according to clinical activity. Topical therapy, 
using 0.05% clobetasol propionate ointment, was also added in many cases. Other systemic 
therapy used in minority cases were: rituximab (1000 mg on day 0 and 14), dapsone (50 
mg/daily), mycophenolate mofetil (1.5-2 gr/day), and intravenous immunoglobulin therapy 
(4 monthly cycles at a dose of 2 g/kg per cycle). Rituximab and intravenous immunoglobulin 
therapy were provided at the Center of Research of Immunopathology and Rare Diseases 
(S. Giovanni Bosco Hospital, Turin, Italy). All patients on corticosteroid therapy were 
recommended to observe a diet low in salt, fat, and calories, and to increase the intake of 
potassium- and protein-rich meals in order to control weight gain, hyperglycaemia, and 
electrolyte imbalance.17 
All patients had also a concomitant anti-fungal treatment against oropharyngeal candidosis, 
this consisting of miconazole gel applied once or twice daily, or nystatin (4 mL qid) or 
fluconazole rinses (5 mL bid). To prevent corticosteroid-induced osteoporosis,18 some 
patients needed also to take sodium clodronate 100 mg/3.3 mL injection monthly, 1000 mg 
of calcium carbonate and 400 IU of Vitamin D daily19 until 2011; later, the usual prescription 
was of alendronic acid (70 mg weekly) and 400 IU of Vitamin D daily. 
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We categorized the adverse effects as follow: 0 = patients who did not have any severe 
adverse reaction; 1 = patients who developed 1 or 2 severe adverse reactions; 2 = patients 
who developed 3 or more severe adverse reactions; 3 = dead patients. 
 
   Clinical data 
The oral mucosal disease severity (MDS) was assessed as mild (only localized to buccal 
mucosa), moderate (buccal and gingivolabial mucosal involvement), and severe (extensive 
oral mucosal involvement).9 The involvement or not of skin and/or other mucosal 
membranes was documented as present or absent. All the patients had a complete 
ophthalmologic and dermatological examination; moreover, a flexible nasopharyngoscope 
was used to visualize the nasal mucosa, epiglottis, pharynx, larynx and proximal 
oesophagus. 
In a theoretical manner, we also subdivided patients based on the date of the initial diagnosis 
[0 = patients diagnosed until 2006; 1 = patients diagnosed since 2007], trying to assess 
whether the increased clinical skills acquired over the years could in some way influence 
therapeutic results. Therapeutic response was assessed by clinical improvement, in term of 
remission of existing lesions. Control of disease activity was defined as ‘the time at which 
new lesions cease to form and established lesions begin to heal’ in accordance with 
international consensus statement on end points and therapeutic response for PV. Outcome 
measures were defined as follows: complete remission off therapy (absence of new or 
established lesions while the patient is off all systemic therapy for at least 2 months); 
complete remission on therapy (absence of new lesions or established lesions while the 
patients is receiving minimal therapy, e.g. ≤ 10 mg/d prednisone or equivalent and/or 
minimal adjuvant therapy for at least 2 months); partial remission on therapy (defined as the 
presence of transient new lesions that heal within one week while the patient is receiving 
minimal therapy, including topical steroids.20 
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Methods were conformed to the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) checklist and statement.21 
The ethics review board of the CIR - Dental School approved the study (CIR-PO 2018/2435). 
 
   Statistical analysis 
The non-normality of the distribution of continuous variables were checked via Kolmogorov-
Smirnov tests, so Kruskall-Wallis tests were performed to evaluate the differences between 
continuous variables. Chi squared or Fisher’s exact tests when appropriate were computed 
to evaluate the differences between qualitative variables. The Spearman’s rank correlation 
coefficient was computed to evaluate the correlation between the delay in diagnosis and the 
mucosal severity involvement at baseline. Odds ratios (ORs) and 95% confidence intervals 
(95% CI) were computed by means of multivariable logistic regression models, in order to 
test the effect of the length of the steroid therapy on the side effects. Models were adjusted 
by sex, date of diagnosis (before 2007 or after) and age at diagnosis. Hypothesis tests were 
2-sided and statistical significance was set at a=0.05. All statistical analyses were performed 
using SAS V9.3 (SAS Institute Inc., NC27513-2414, USA). 
 
RESULTS 
   Demographic features 
The study group comprised 95 unrelated Caucasian patients (60 female and 35 male), 
together with 2 female and 1 Afro-Caribbean male (F : M; 1.65 : 1), mean age 54.56 (±14.95). 
The majority of the patients (24, 24.49%) was in the 6th decade of life. 
 
   Oral disease profile and mucosal or cutaneous involvement 
The duration of oral symptoms before definitive diagnosis varied from 1 to 36 months, 
leading to an average delay of 24 weeks (mean times of 23.42 weeks for male and 20.20 
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weeks for female). The delay of diagnosis was however not statistically associated with the 
degree of oral involvement (rho = 0.13; P = 0.20). 
By definition, all patients had oral lesions at presentation. Considering the MDS index, it was 
mild in 20 cases (20.41%), moderate in 48 (48.98%) and severe in 30 cases (30.61%). 
Patients diagnosed since 2007 statistically had a worse oral involvement (p= 0.01) (Table 
1). The buccal mucosae were the single most common site (32.93%), followed by the palate 
(22.76%), tongue plus floor of the mouth (18.29%%), gingiva (17.48%), and lips (8.54%). 
Eleven patients (11.22%) had only gingival lesion at the time of presentation. Soreness was 
the most commonly reported oral symptom in almost all patients, while only 30 (30.61%) of 
them described the pain as being notably severe.  
Forty-three patients (43.87%) had other mucosal involvement, being the pharynx clinically 
affected in 33 cases, nasal mucosa in 11, vagina in 4, larynx in 10 and oesophagus in 3; 2 
patients had also the involvement of anal mucosa. Conjunctiva was affected in 4 patients.  
Forty-one patients (41.83%) presented with cutaneous manifestation, of whom 6 developed 
cutaneous blisters after starting systemic treatment during the follow-up time. Skin 
involvement was statistically more evident in patients diagnosed since 2007 (p = 0.04). 
 
   Associated diseases 
The medical histories included essential hypertension (22 patients), osteoporosis (7 
patients) and one patient each had hepatitis C infection, cardiomyopathy, psoriasis, 
depression, hypothyroidism, ulcerative rectocolitis, allergic rhinitis, prostatic adenoma and 
colon cancer. All those patients with pre-existing associated diseases were treated after 
consultation with relevant medical specialists. Medical histories of 54 patients were 
unremarkable.  
 
   Treatment provided 
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Ninety-five patients were treated initially with systemic corticosteroids per os. During this 
treatment time [lasting on average 48 months (±49.59)], 81 patients received corticosteroid-
sparing adjunctive therapy as it follows: 48 with azathioprine, 16 with intravenous rituximab, 
13 with mycophenolate mofetil, 3 with intravenous immunoglobulin therapy and 1 with 
dapsone. The use of azathioprine statistically decreased since 2007 in a statistical manner, 
differently from the use of rituximab which increased but not statistically (Table 1). 
Three patients (with very mild lesions) controlled their disease only by using topical 
corticosteroids; 63 patients, together with the systemic therapy, used topical clobetasol 
mainly to control oral limited soreness, or restricted skin and nasal lesions. 
We gradually tapered the corticosteroid down, for patients in remission (starting after having 
reached at least the 75% of oral lesion remission), until we reached a maintenance dose of 
5-20 mg daily. If the lesions did not relapse, the corticosteroid was again tapered until a 
maintenance dose of 2.5 mg every two, three or four days, and then stopped.  
 
   Treatment outcome 
Eighty-six of the 98 patients were still being followed at the Oral Medicine Unit when this 
study was performed. Patients were followed-up for 85.12 months on average (±59.35) with 
a recorded median of 73.50 months (Table 2).  
The average time to achieve complete clinical remission was 3.9±2.72 months after 
commencement of therapy. In 39 (41.05%) of the 95 patients who received systemic 
treatment there was the complete resolution of disease in less than 6 months, and at the 
end of the follow-up period they were not under treatment; they remained under steroid 
therapy for 53.15 months (± 38.89). Forty-one (43.15) patients were disease free but still 
taking immunosuppressive therapy but tapering it down, for 61.51 months (± 51.93).  Fifteen 
(15.8%) patients did not respond, having been under systemic therapy for 72.16 months (± 
63.51). 
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Females tended to have a higher percentage of unresponsive lesions than males (22.95% 
vs 10.81%) (p = 0.0305). 
The use of azathioprine seemed not to be related to a better percentage of possible 
improvement with the 25% of total treated cases who cannot tolerate it (Table 1). Such 
conclusion cannot be drawn for the other immunosuppressive agents, as their limited use 
did not allow the same kind of analysis.  
Patients who presented with joint skin or mucosal involvement had higher unresponsive 
rates compared to patients with exclusive oral involvement (P = 0.0481, P = 0.0379, 
respectively). Similarly, patients with greater oral involvement had worse rates of complete 
response (P = 0.0337). Differently, no differences were reported if considering the oral site 
of involvement (P = 0.6506). 
Differently, age at baseline and diagnostic delay did not seem to influence the outcome of 
the therapy in terms of oral lesions remission. 
Patients diagnosed since 2007 had the similar chance of being under remission if compared 
to those diagnosed before (p = 0.89), but they were treated with corticosteroids for a shorter 
period (p = 0.01). 
 
   Adverse effects 
Weight gain and cushinoid features were observed almost in every patient who took 1.5 
mg/kg/day of systemic prednisone, after approximately 1-3 months of treatment. These 
changes were however reversible after the decrease of the induction dose. 
Sixty-nine patients (72.63%) on systemic treatment developed detectable adverse effects 
from the immunosuppressive drugs. Among these, 54 patients developed less than 2 
adverse effects while 15 patients manifested 3 or more. It was possible to report 15 cases 
of hypertension (plus 6 cases of other cardiovascular problems), 11 cases of 
hyperglycaemia, 23 cases of osteoporosis, 9 cases of gastric diseases, 10 cases of mood 
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disorders, 3 cases of cataract and 2 cases of pneumonia. Other unusual effects, reported 
only once, were detailed as follow: walking problems, hair loss, folliculitis, tremor, 
hypokalaemia, and erythroderma. One patient had a myocardial infarction after 5 weeks of 
therapy with steroids alone and a femoral fracture after 20 weeks.  
Two fatal outcomes, likely linked to the therapy, were recorded over the follow-up period 
(2.10% of patients who underwent systemic management; 2.04% of the total study 
population). 
Table 3 described the effect of the length of the steroid therapy (LST) on the side effects 
(also adjusted by sex, date of diagnosis and age at the time of first diagnosis). It was possible 
to state that each additional year of steroid therapy ensures 47% chance of developing 1 or 
2 side effects, and 63% chance of developing more than 3 side effects (ORs 1.487 CI 1.162-
1.903; ORs 1.536 CI 1.107-2.130, respectively). 
 
DISCUSSION 
There have been few studies describing the oral manifestations and treatment outcomes in 
PV. However, it is though that in most cases, the oral lesions are the first manifestation of 
the disease13,14,22 and a significant proportion of PV patients can just have oral lesions.12-16  
In all our cases the oral lesions were the first manifestation of the disease, in the form of 
blisters and/or ulcers, sometimes associated with skin disease or other mucosal membranes 
involvement. The most commonly affected sites in the present study were the buccal 
mucosae and the gingival, in accordance with recent findings.23-25  
PV affects all races and both sexes, and is more frequent in middle aged and elderly 
patients,3 with a peak incidence between the fifth and sixth decades of life. In this report, we 
described 98 patients with PV, with a preponderance of female, and about two third of them 
were in the 4th to 6th decade of their life.  The youngest patient in this report was an 18-year-
old female and the oldest being an 85-year-old woman.  
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Intra oral involvement usually precedes the development of extraoral disease.3,8 In out 
cohort, many patients were at first misdiagnosed, frequently as having aphthous or herpetic 
stomatitis or candidosis, and erroneously treated for a long period. Male patients tended to 
have symptoms for longer periods before receiving a definitive diagnosis than females 
(mean times of 23.42 weeks for male and 20.20 weeks for female), and this is similar to 
previous findings.13  
The early diagnosis of PV has been suggested to be fundamental to achieve a long-term 
remission with minimal adverse-effects and healthier prognosis.23, 24 Nonetheless, in our 
series, diagnostic delay did not seem to be statistically related to faster improvement, neither 
in terms of duration of the corticosteroid therapy nor in absolute terms of disappearance of 
oral signs and symptoms. This could possible explained because previously reported 
diagnostic delays in PV were possibly greater than in our cohort but also because often in 
published studies there was no clear distinction between cutaneous and oral involvement. 
Indeed, in our series skin involvement was correlated with a worse prognosis. Moreover, 
female patients tended to have a statistically worse prognosis if compared to males; this 
type of information has never been documented in an oral clinical setting. 
Cases of oral PV usually responded very well to the corticosteroid therapy, and in our study 
the average time for a complete clinical remission was quite similar to that reported by others 
in similar clinical setting,16 commonly less than six months. 
Ideally, the management of PV aims to induce and maintain clinical remission with minimum 
adverse effects. Because of the lack of international agreed recommendations, either the 
dosage of corticosteroids and choice of adjuvant agents usually reflect the experience of 
clinicians at various centres.23,26 
A review of 77 studies, reported a mortality rates of 70.5% before the advent of systemic 
corticosteroids, 21.4% when steroids were used, and 3.7% when steroids were pooled with 
adjuvant drugs, and the latter is similar to our results.27 
 13 
At the end of 2012, an interim analysis of collected data showed that azathioprine was poorly 
effective in achieving disease control if used together with corticosteroids, with many 
patients unable to tolerate it, similarly to what has been recently reported in cases of 
mucosal-predominant PV.28 Since then we decided to stop prescribing azathioprine as 
steroid sparring partner. This seems quite in contradiction with very recent findings from a 
retrospective study form Japan, suggesting that azathioprine monotherapy could be a viable 
treatment option for mild PV.29 However, this study enrolled just 5 patients and the exact 
oral involvement was not reported. 
One particular strength of our report is the duration of the follow-up. Patients have been 
followed up from 6 months to 20 years and 57 patients have been followed for more than 5 
years. This considerable period allowed us to show that shorter corticosteroid therapies 
produced less adverse reactions but similar results in terms of complete oral remission 
compared to longer ones. Moreover, whereas age at baseline or diagnostic delay did not 
seem to influence the outcome of the treatment, patients with skin and mucosal involvement 
or with greater oral involvement had lower remission rate and needed longer corticosteroid 
therapy.28 
We would also emphasize that our findings suggest that the increased experience of the 
clinicians in treating PV could have led to a statistically significant shorter period of 
corticosteroid therapy. However, this could have also been influenced by the increase use 
of rituximab as a second line treatment. Notably, it has recently been reported that first-line 
use of rituximab plus short-term prednisone for patients with PV/pemphigus foliaceous is 
more effective than prednisone alone, and has fewer adverse events.29 Further researches 
in oral PV should be likely directed towards the use of rituximab as first therapeutic option, 
to assess whether this treatment modality allows a faster resolution of the mucosal lesions, 




This is one of the largest groups of oral PV patients with such long follow up ever reported. 
We confirm that the disease can be effectively controlled and followed up also in an oral 
medicine unit with remission rates similar to dermatological cohorts. According to our 
findings, systemic corticosteroid should be still considered, at least for predominant oral 
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